SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-435149"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-435149" > The dapagliflozin a...

  • Wheeler, David C.UCL, Dept Renal Med, London, England. (författare)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020-08-30
  • OXFORD ENGLAND :Oxford University Press (OUP),2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-435149
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-435149URI
  • https://doi.org/10.1093/ndt/gfaa234DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Stefansson, Bergur, VAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (författare)
  • Batiushin, MikhailRostov State Med Univ, Dept Nephrol, Rostov Na Donu, Russia. (författare)
  • Bilchenko, OleksandrKharkiv Med Acad Postgrad Educ, Kharkiv, Ukraine. (författare)
  • Cherney, David Z., IUniv Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada.;Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada. (författare)
  • Chertow, Glenn M.Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA.;Stanford Univ, Dept Med, Sch Med, Stanford, CA USA. (författare)
  • Douthat, WalterHosp Privado Univ Cordoba, Dept Nephrol, Cordoba, Argentina. (författare)
  • Dwyer, Jamie P.Vanderbilt Univ, Med Ctr, Nashville, TN USA. (författare)
  • Escudero, ElizabethCayetano Heredia Univ, Hosp Arzobispo Loayza, Div Nephrol, Lima, Peru. (författare)
  • Pecoits-Filho, RobertoPontificia Univ Catolica Parana, Sch Med, Curitiba, Parana, Brazil.;Arbor Res Collaborat Hlth, Ann Arbor, MI USA. (författare)
  • Furuland, HansUppsala universitet,Njurmedicin(Swepub:uu)hansfl (författare)
  • Gorriz, Jose LuisUniv Valencia, Univ Clin Hosp, Dept Nephrol, INCLIVA, Valencia, Spain. (författare)
  • Greene, TomUniv Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USA. (författare)
  • Haller, HermannHannover Med Sch, Hannover, Germany. (författare)
  • Hou, Fan FanSouthern Med Univ, Natl Clin Res Ctr Kidney Dis, Dept Med, Div Nephrol, Guangzhou, Peoples R China. (författare)
  • Kang, Shin-WookYonsei Univ, Dept Internal Med, Div Nephrol, Coll Med, Seoul, South Korea. (författare)
  • Isidto, ReyHealthlink Med Dent Surg Clin & Diagnost Ctr, Iloilo, Philippines. (författare)
  • Khullar, DineshMax Super Special Hosp, Dept Nephrol & Renal Transplant Med, New Delhi, India. (författare)
  • Mark, Patrick B.Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. (författare)
  • McMurray, John J., VUniv Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. (författare)
  • Kashihara, NaokiKawasaki Med Sch, Dept Nephrol & Hypertens, Okayama, Japan. (författare)
  • Nowicki, MichalMed Univ Lodz, Dept Nephrol Hypertens & Kidney Transplantat, Lodz, Poland. (författare)
  • Persson, FrederikSteno Diabet Ctr Copenhagen, Gentofte, Denmark. (författare)
  • Correa-Rotter, RicardoNatl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico. (författare)
  • Rossing, PeterSteno Diabet Ctr Copenhagen, Gentofte, Denmark.;Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark. (författare)
  • Toto, Robert D.UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA. (författare)
  • Umanath, KausikHenry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA.;Wayne State Univ, Div Nephrol & Hypertens, Detroit, MI USA. (författare)
  • Van Bui, PhamPham Ngoc Thach Med Univ, Ho Chi Minh City, Vietnam. (författare)
  • Wittmann, IstvanUniv Pecs, Dept Med 2, Med Sch, Pecs, Hungary.;Univ Pecs, Nephrol Diabet Ctr, Med Sch, Pecs, Hungary. (författare)
  • Lindberg, MagnusAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (författare)
  • Sjostrom, C. DavidAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (författare)
  • Langkilde, Anna MariaAstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (författare)
  • Heerspink, Hiddo J. L.Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands. (författare)
  • UCL, Dept Renal Med, London, England.AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Nephrology, Dialysis and TransplantationOXFORD ENGLAND : Oxford University Press (OUP)35:10, s. 1700-17110931-05091460-2385

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy